CORRECTION article

Front. Endocrinol., 03 November 2022

Sec. Thyroid Endocrinology

Volume 13 - 2022 | https://doi.org/10.3389/fendo.2022.1073400

Corrigendum: Update on genistein and thyroid: an overall message of safety

  • 1. Section of Physiology and Human Nutrition, Department of Biochemical, Physiological and Nutritional Sciences, University of Messina, Messina, Italy

  • 2. Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy

  • 3. Section of Endocrinology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy

  • 4. Master on Childhood, Adolescent and Women’s Endocrine Health, University of Messina, Messina, Italy

  • 5. Interdepartmental Program of Molecular and Clinical Endocrinology, and Women’s Endocrine Health, University Hospital of Messina, Messina, Italy

In the published article, the Conflict of Interest statement was incorrectly filed. The correct Conflict of Interest statement appears below.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Statements

Conflict of interest

FS has received research support from Primus Pharmaceuticals for work on genistein. Authors FS and AB are co-inventors on patents referring to genistein activity.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Summary

Keywords

genistein, isoflavones, soy, safety, thyroid

Citation

Marini H, Polito F, Adamo EB, Bitto A, Squadrito F and Benvenga S (2022) Corrigendum: Update on genistein and thyroid: an overall message of safety. Front. Endocrinol. 13:1073400. doi: 10.3389/fendo.2022.1073400

Received

18 October 2022

Accepted

19 October 2022

Published

03 November 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2022

Updates

Copyright

*Correspondence: Salvatore Benvenga,

†Herbert Marini, Francesca Polito, and Elena B. Adamo have contributed equally to this work

This article was submitted to Thyroid Endocrinology, a section of the journal Frontiers in Endocrinology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics